President Donald Trump on Thursday defended his administration's calculations on drug pricing, which critics have called mathematically impossible. Speaking at an Oval Office event on health care affordability, Trump argued that there are 'two ways of calculating' the numbers, without providing further details.
Controversy Over Drug Price Claims
The controversy began when the Trump administration released figures suggesting dramatic reductions in drug prices under his policies. However, independent analysts quickly pointed out that the numbers did not add up. For instance, the administration claimed that average drug prices had dropped by over 50%, but actual market data showed only modest declines.
During the event, Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr. and Chris Klomp, director of the Centers for Medicare and Medicaid Services. Klomp stood by the administration's figures, stating that they reflected a 'comprehensive approach' to measuring savings.
Expert Reactions
Health economists have been skeptical. Dr. Sarah Johnson, a health policy expert at Harvard, said, 'The claimed reductions are not supported by any standard economic model. It appears the administration is using a different baseline or including savings that haven't materialized.'
The White House has not released the detailed methodology behind the calculations. When pressed by reporters, Trump dismissed the criticism, saying, 'These are very smart people. They know what they're doing. The fake news media just doesn't understand.'
Political Implications
The dispute comes as Trump faces scrutiny over his health care record ahead of the midterm elections. Drug pricing has been a key issue for voters, and the administration has touted its efforts to lower costs. However, the mathematical discrepancies could undermine public trust.
Democratic leaders have seized on the controversy. Senator Elizabeth Warren called for a full investigation, stating, 'The American people deserve transparency, not fantasy numbers.'
Meanwhile, the administration continues to push forward with its health care agenda, including new proposals to cap insulin prices and expand Medicare negotiations. Whether the drug pricing claims will hold up under scrutiny remains to be seen.
